The Pharmaceutical Journal·3 min read·medium
Incretin-based weight-loss drugs should not be deliberately continued in pregnancy, consensus guidelines state
✦AI Summary
New international consensus guidelines advise against the deliberate use of GLP-1 weight-loss medications during pregnancy. While the guidelines note no increased risk of congenital anomalies from early inadvertent exposure, they emphasize the need for multidisciplinary care for women of reproductive age.
Consensus guidelines for the use of GLP-1 medications in pregnancy, breastfeeding and postpartum has been published following an international review.
healthscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in